84254-97-7

Usage

Chemical Properties

Pale yellow crystalline powder

Upstream product

• 3612-20-2 1-phenylmethyl-4-piperidone 
• 143-33-9 sodium cyanide 
• 6091-44-7 piperidine hydrochloride 
• 110-89-4 piperidine 
• 75-86-5 2-hydroxy-2-methylpropanenitrile 
• 6094-60-6 1-benzyl-4-hydroxypiperidine-4-carbonitrile 

Downstream Products

• 476013-09-9 N,N-dimethyl-1-benzyl-4-(piperidin-1-yl)piperidine-4-carboxamide 
• 476013-10-2 N-methyl-1-benzyl-4-(piperidin-1-yl)piperidine-4-carboxamide 
• 1762-50-1 1'-benzyl-octahydro-[1,4']bipyridinyl-4'-carboxylic acid amide 
• 726185-53-1 1'-(phenylmethyl)-[1,4']bipiperidinyl-4'-carboxylic acid 
• 3543-30-4 1'-benzyl-4'-phenyl-decahydro-[1,4']bipyridinyl 

Relevant academic research and scientific papers

Dual NK2/NK3-antagonists, pharmaceutical compositions comprising them, and processes for their preparation

Dual NK2/NK3-antagonists corresponding to formula I: and physiologically compatible salts of such compounds in which X and R1 to R5 have specific defined meanings, pharmaceutical compositions containing such compounds, methods of using such compounds to treat or inhibit disorders mediated by tachykinin receptors, and a process for preparing such compounds.

Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same

The invention relates to compounds of formula: as well as their salts with inorganic or organic acids, their solvates and/or their hydrates, which exhibit a very high affinity both for the human NK2 receptors for neurokinin A and for the human NK3 receptors for neurokinin B and are antagonists of the said receptors. The invention also relates to their method of preparation, the pharmaceutical compositions containing them and their use for the preparation of medicaments.